ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Havrix 1440, Injektionssuspension - 
00558002 GlaxoSmithKline AG
Havrix 1440, Injektionssuspension03.09.1993
  03.09.1993
Hepatitis A, Inactivated, Whole Virus (J07BC02) 
WHO-DDD 
08.08. 
08.08. 
B  
Yes 
IP 
31.84Yes
    
10 %51.05
  
7680005580023Impfstoffe
  
Composition
Vaccinum adsorbatum: hepatitis-A-virus inactivatus (HM175) 1440 U. corresp. proteina max. 0.4 µg, aluminii hydroxidum hydricum ad adsorptionem corresp. aluminium 0.5 mg, aminoacida cum phenylalaninum 166 µg, dinatrii phosphas, kalii dihydrogenophosphas, natrii chloridum, kalii chloridum, polysorbatum 20, aqua ad iniectabile, ad suspensionem pro 1 ml corresp. natrium max. 3.6 mg et kalium max. 0.5 mg, residui: neomycini sulfas.
Packungsbestandteile
Injection suspension 
  
 
Active AgentDoseadditional_information
 1440 U/ml correspond Protein 0.4 µg/mlVaccinum adsorbatum
BAG: Active AgentDose
 1440 U
 
Inactive agentsDose
  
 166 µg/ml
Disodium Phosphate 
Potassium Chloride 
Potassium Dihydrogenophosphate 
Sodium Chloride 
  
 
Source
Data was imported : 08.08.2023 Swissmedic Registration : Sequence : Product name : Registration owner: : Product group : Index Therapeuticus (BSV) : Medication Code : Date of registration : Valid until : Package number : Show package size : Commercial Form/Unit : Swissmedic categorie. : Active Agents : Composition :
 
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home